Alcon Inc. reports developments in eye care through its Surgical and Vision Care businesses. Company news commonly covers quarterly results, constant-currency sales trends, product-launch momentum and portfolio updates across cataract and vitreoretinal surgical systems, intraocular lenses, contact lenses, lens-care products and ocular health.
Recurring updates also include launches and milestones for products such as Clareon, PanOptix, Vivity, TOTAL30, Precision7, Tryptyr and Unity, along with annual general meeting items, board elections, compensation votes, dividends, share repurchase authorizations, acquisitions, integration costs, R&D spending and other governance or capital-allocation actions.
Broadwood Partners (NASDAQ: STAA), which holds 27.5% of STAAR outstanding shares, sent a letter to STAAR Surgical’s board on October 17, 2025 urging directors to allow a timely shareholder vote on the proposed sale to Alcon (NYSE: ALC). Broadwood urges shareholders to vote AGAINST the acquisition announced August 5, 2025, arguing the board pursued a poorly designed process and an inadequate price.
Broadwood warns the board against delaying the October 23, 2025 vote or issuing misleading statements, and says shareholders and proxy advisors oppose the deal; it calls for the board to accept the vote result and work with shareholders if the transaction is rejected.
Summary not available.
Summary not available.
STAAR Surgical (NASDAQ: STAA) reiterated its board's unanimous recommendation that stockholders vote FOR the merger with Alcon on the white proxy card.
Key points: Alcon's offer is $28.00 per share in cash (a 59% premium to the 90-day VWAP). STAAR contrasts this with Broadwood's position and a prior price of $18.49 per share, warning a vote against could invite control shifts and valuation pressure. Stockholders are urged to contact STAAR's proxy solicitor for voting assistance.
Summary not available.
Defender Capital, a long-term shareholder owning approximately 1.5% of STAAR Surgical (NASDAQ: STAA), announced on October 7, 2025 its opposition to the proposed sale of STAAR to Alcon (NYSE: ALC) for $28 per share. Defender said the $28 price significantly undervalues STAAR, noting the STAAR board rejected a prior $58 per share cash offer from Alcon sixteen months earlier. Defender cited recent positive projections and outlook from STAAR management and argued there is no compelling reason to sell at the proposed valuation. Defender described the transaction as ill-advised and said it does not reflect STAAR’s standalone prospects.
Yunqi Capital (NASDAQ:STAA), a 5.1% shareholder, reiterated opposition to STAAR Surgical’s proposed sale to Alcon announced Aug 5, 2025, arguing the deal undervalues STAAR and mischaracterizes its China outlook.
Yunqi says recent revenue weakness (~10% decline 2023–2025) was driven by temporary China distributor inventory corrections (quarterly China revenue drops of 82%, 99%, 92% in late 2024–mid 2025) and that inventory has returned to historical levels per STAAR’s 10-Q. Yunqi highlights rising operating expenses (annualized run-rate from ~$150M in 2022 to ~$250M in 2024), U.S. headcount growth (~+400), and CEO merger-related payouts (~$24M of ~$55M total) as concerns. Yunqi proposes cost cuts, channel fixes and buybacks to unlock value instead of the sale.
Summary not available.
STAAR (NASDAQ: STAA) highlighted independent industry analyst commentary endorsing its proposed cash merger with Alcon at $28 per share. Analysts cite a ~59% premium to STAAR’s 90‑day VWAP, an implied total equity value of ~$1.5 billion and multiples ranging from ~4.7x FY26 sales to ~6x 2025 sales. STAAR warned of sustained standalone risks driven by severe China weakness (China revenue fell to $5.3M, -92% Y/Y) and channel inventory issues. The STAAR Board unanimously recommends voting “FOR” the merger at a special meeting on October 23, 2025.
Broadwood Partners (holder of approx. 27.5% of STAAR common stock) published an 81-page presentation on October 3, 2025 urging STAAR stockholders (NASDAQ: STAA) to vote "AGAINST" the proposed acquisition by an affiliate of Alcon (NYSE: ALC). Broadwood says the deal, announced August 5, 2025, comes "at the wrong time, after the wrong process, and at the wrong price" and contends the board failed to run a responsible sale process and agreed to a price that "significantly undervalues" STAAR. The presentation is posted at LetSTAARShine.com.